PUBLISHER: The Business Research Company | PRODUCT CODE: 1414430
PUBLISHER: The Business Research Company | PRODUCT CODE: 1414430
“Molecular Cytogenetics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on molecular cytogenetics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for molecular cytogenetics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The molecular cytogenetics market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Molecular cytogenetics encompasses a suite of techniques employed to study the entire genome or specific targeted DNA sequences. It involves understanding the structural and functional organization of chromosomes and nuclei, exploring genome variations, gene expression, evolution, chromosome anomalies, and genomic variations within medical genetics and tumor genetics.
The primary offerings within the molecular cytogenetics market include instruments, kits and reagents, software, services, as well as consumables or accessories. Software pertains to sets of instructions, data, or programs utilized to operate computers and perform specific tasks. The technologies employed encompass comparative genomic hybridization, fluorescence in situ hybridization, immunohistochemistry, karyotyping, and other related methodologies. Applications of these technologies extend to areas such as genetic disorders, cancer research, personalized medicine, among others. End-users encompass clinical and research laboratories, academic research institutes, pharmaceutical and biotechnology companies, and various other entities involved in these scientific pursuits.
The molecular cytogenetics market research report is one of a series of new reports from The Business Research Company that provides molecular cytogenetics market statistics, including molecular cytogenetics global market size, regional shares, competitors with an molecular cytogenetics market share, detailed molecular cytogenetics market segments, market trends and opportunities, and any further data you may need to thrive in the molecular cytogenetics industry. This molecular cytogenetics market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The molecular cytogenetics market size has grown rapidly in recent years. It will grow from $2.65 billion in 2023 to $2.93 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the historical period can be linked to several factors. These include the increase in cases related to genetic disorders and cancer, a rising demand for personalized medicine, substantial research and development activities in the life sciences domain, clinical applications focusing on prenatal and postnatal diagnosis, and the implementation of global initiatives aimed at advancing genomic medicine.
The molecular cytogenetics market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The expansion observed in the historical period can be linked to several factors. These include the increase in cases related to genetic disorders and cancer, a rising demand for personalized medicine, substantial research and development activities in the life sciences domain, clinical applications focusing on prenatal and postnatal diagnosis, and the implementation of global initiatives aimed at advancing genomic medicine.
The anticipated rise in genetic disorders and cancer cases is projected to be a significant driver for the molecular cytogenetics market growth. This field focuses on examining tissue and blood samples to identify chromosome alterations indicating genetic conditions or certain cancer types. Forecasts by the American Cancer Society suggest a global surge in new cancer cases and related deaths by 2040. In 2022, the United States alone witnessed over 1.9 million new cancer cases and more than 600,000 deaths, including a daily average of approximately 350 deaths from lung cancer. These statistics underscore the market's growth fueled by the increasing incidence of genetic disorders and cancer.
The expansion of personalized medicine stands as a catalyst for the molecular cytogenetics market. Personalized medicine customizes healthcare based on individual patient traits. Molecular cytogenetics, by deciphering chromosomal alterations and genetic irregularities, offers vital insights for tailored therapy approaches. In 2021, the FDA greenlit 17 new personalized medicines, constituting over a quarter of the agency's recent drug approvals. This intersection highlights how the surge in personalized medicine contributes to the burgeoning molecular cytogenetics market.
A notable trend in the molecular cytogenetics market involves product innovation, with major companies spearheading advancements. Leading firms are leveraging novel technologies to fortify their market presence. For example, Agilent Technologies Inc introduced three new microarrays in March 2021, catering to cytogenetic laboratories' needs in prenatal and postnatal research. These arrays, the Agilent GenetiSure Cyto microarrays, boast updated content relevant to clinical settings. Their high-resolution capabilities detect variations linked to developmental delays, neuropsychiatric disorders, intellectual disabilities, and congenital anomalies in DNA samples.
Companies within the molecular cytogenetics domain are actively developing innovative products, exemplified by the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit. This kit, unveiled by Lexogen in November 2023, reshapes single-cell RNA sequencing by employing an RNA-amplification-based method that detects nearly every mRNA molecule within a cell. It captures 95% of expressed genes at a depth of 1 million reads, enabling the detection of even a single gene copy in a cell. The kit's remarkable sensitivity relies on the groundbreaking THOR (T7 High-resolution Original RNA amplification) technology, surpassing limitations associated with low-copy transcripts.
In January 2022, Calibre Scientific, a US-based supplier of life science reagents, tools, instruments, and various consumables to laboratory research, diagnostics, industrial, and biopharmaceutical sectors, successfully acquired AmpliTech for an undisclosed sum. This strategic acquisition allows Calibre Scientific to incorporate another significant brand into its European distribution division. AmpliTech, headquartered in France, specializes in molecular pathology, cytogenetics, and molecular genetics, contributing valuable expertise and products in these domains.
Major companies operating in the molecular cytogenetics market report are Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, CytoTest Inc., Danaher Corporation, Illumina Inc., PerkinElmer Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Oxford Gene Technology Limited, Affymetrix Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, F. Hoffmann-La Roche AG, Bi Biological industries, Cytognomix Inc., Empire Genomics LLC., Genial Genetic Solutions Ltd., BioChain Institute Inc., BioGenex Laboratories Inc., Bio-Techne Corporation, Cytocell Ltd., Kreatech Diagnostics B.V., Leica Biosystems Nussloch GmbH, MetaSystems Group Holding GmbH, MolecularMD Corporation, Natera Inc., Opko Health Inc., PathGroup Inc., Roche Diagnostics Corporation, SciGene Corporation, SkylineDx B.V.
North America was the largest region in the molecular cytogenetics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global molecular cytogenetics market report during the forecast period. The regions covered in the molecular cytogenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the molecular cytogenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The molecular cytogenetics market consists of revenues earned by entities by providing in situ hybridization, and banding techniques. The market value includes the value of related goods sold by the service provider or included within the service offering. The molecular cytogenetics market also includes sales of diagnostic tools, and instrumentation which are used for providing molecular cytogenetics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.